KYAN Technologies: Difference between revisions
Created page with "{{Draft}} {{Infobox Startup |logo=Kyan therapeutics logo.jpg |status=Active |website=https://kyantechnologies.com/ |vertical=Medtech, Biotechnology |trl=Deployment (TRL 7-8) |latest_funding=Pre-Series A |founding_year=2016 |headquarters=Singapore }} A brief overview of {{PAGENAME}} here ==Technology== Describe the underlying science and technology of the startup here. Ideally, it should provide a layman introduction of any key differentiators and/or novel or propriet..." |
No edit summary |
||
| Line 10: | Line 10: | ||
|headquarters=Singapore | |headquarters=Singapore | ||
}} | }} | ||
KYAN Technologies is a Singapore-based startup that is developing a platform for [[precision medicine]] for both treatment and drug development. | |||
==Technology== | ==Technology== | ||
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ differnt cancer types. | |||
==Traction== | ==Traction== | ||